Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15336580 | 1.00 | NPSR1 (0.51) | NPSR1L3MBTL1LTA4HHDAC3HDAC1 | |
| SCHEMBL15320116 | 0.89 | NPSR1 (0.52) | NPSR1L3MBTL1LTA4HHDAC3HDAC1 | |
| SCHEMBL15318909 | 0.89 | NPSR1 (0.52) | NPSR1L3MBTL1LTA4HHDAC3HDAC1 | |
| SCHEMBL15319101 | 0.83 | MEN1 (0.39) | NPSR1L3MBTL1 | |
| SCHEMBL16552687 | 0.82 | NPSR1 (0.46) | NPSR1L3MBTL1 | |
| SCHEMBL16552688 | 0.82 | NPSR1 (0.46) | NPSR1L3MBTL1 | |
| SCHEMBL1711414 | 0.80 | L3MBTL1 (0.50) | NPSR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL8300754 | 0.78 | L3MBTL1 (0.52) | NPSR1L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL1913578 | 0.78 | L3MBTL1 (0.49) | NPSR1L3MBTL1LTA4HHDAC3HDAC1 | |
| SCHEMBL1913579 | 0.78 | L3MBTL1 (0.49) | NPSR1L3MBTL1LTA4HHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | NPSR1 2765/4885L3MBTL1 388/4885LTA4H 253/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | NPSR1 2765/4885L3MBTL1 388/4885LTA4H 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.